The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare

FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare

March 12, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The U.S. Food and Drug Administration (FDA) has issued a boxed warning for febuxostat after a safety study found an increased risk of heart-related death, as well as death from all causes, with febuxostat. The agency has also approved colchicine as an oral solution for prophylaxis of gout flares in adults.

You Might Also Like
  • European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat
  • FDA Approves Duzallo for Hyperuricemia in Patients with Uncontrolled Gout
  • FDA Enforcement Against Injectable Colchicine
Explore This Issue
April 2019
Also By This Author
  • Adalimumab & Infliximab Remain in Newborns after Delivery

Safety Risk with Febuxostat
The FDA is alerting healthcare providers and patients about the risk of death associated with the use of febuxostat (Uloric), which was approved in 2009 to treat adults with gout. A clinical safety trial found an increased risk of heart-related death, as well as death from all causes, with febuxostat. This finding is a higher risk of death compared with allopurinol.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The FDA is updating the treatment’s prescribing information to require a boxed warning.

Healthcare professionals should reserve the use of febuxostat for cases in which allopurinol fails to work and for patients who can’t tolerate allopurinol. Patients should be counseled about the cardiovascular risks of using febuxostat. Advise them to seek medical attention immediately if they experience any of the following symptoms: chest pain, shortness of breath, rapid or irregular heartbeat, numbness or weakness on one side of the body, dizziness, trouble talking and/or sudden severe headache.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients should tell their healthcare professional if they have a history of cardiovascular problems or stroke. Patients should not stop taking febuxostat without discussing it with their healthcare provider first.

FDA Approves Colchicine Oral Solution
On Feb. 26, the FDA approved colchicine (Gloperba) in an oral solution of 0.6 mg/5 mL for prophylaxis of gout flares in adults.2 This treatment form enables easy dosage adjustments for patients, such as the elderly, who cannot swallow solid forms. It also enables renally adjusted doses.

The treatment is cherry flavored and will come in a 150 mL bottle that can be stored at room temperature.3 It’s expected to be available this summer.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. U.S. Food and Drug Administration. Drug safety and availability: FDA adds boxed warning for increased risk of death with gout medicine Uloric (febuxostat). 2019 Feb 19.
  2. ROMEG Therapeutics LLC. News release: ROMEG Therapeutics receives FDA approval of Gloperba (colchicine) for prophylaxis of adult gout flares. 2019 Feb 26.
  3. ROMEG Therapeutics LLC. Our products: Gloperba. 2019.

Filed Under: Drug Updates, Safety Tagged With: cardiovascular, Colchicine, Drug Safety, Febuxostat, Food and Drug Administration, Gout, Safety, U.S. Food and Drug Administration (FDA)Issue: April 2019

You Might Also Like:
  • European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat
  • FDA Approves Duzallo for Hyperuricemia in Patients with Uncontrolled Gout
  • FDA Enforcement Against Injectable Colchicine
  • New Study Raises Cardiovascular Questions about Febuxostat for Gout

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.